Cathie Wood’s ARK Invest Shifts 2026 Strategy, Heavily Bets on Gene Editing Technology

Life Science

Novo Nordisk Launches Oral Weight-Loss Drug, Shifting the $100 Billion Market Landscape

Life Science

Nektar Therapeutics Too Risky? This Biotech Stock Offers a Safer Bet

Life Science

Can UnitedHealth’s Jan. 27 Report Reverse Its Stock Slump?

Financial Service, Life Science

Is Pfizer Stock, Now Under $25, a Buy?

Life Science

Why Can These Two Growth Stocks Continue to Outperform the Market Until 2031?

Life Science, Technology

Eli Lilly Plans to Acquire Abivix, Could This Deal Become a New Growth Engine?

Life Science

Bristol-Myers Squibb Bets on the Future, Which Pipelines Will Become the New Pillars of Growth? 

Life Science

“Big Short” Investor Burry Goes Long on Molina, Stock Jumps

Financial Service, Life Science

Towards 2026, Focusing on Three High-Potential Biotechnology Companies

Life Science

Can These Two Battered Biotech Stocks Stage a Comeback in 2026?

Life Science

Who Will Lead in 2026? Analysts Identify the Next Cohort of U.S. Growth Stocks

Financial Service, Life Science, Technology

Bold Forecast: Executive Order Paves Way for Federal Cannabis Legalization by 2026

Cannabis

Drug Approval and Acquisition Potential Form a “Double Boost,” Providing Strong Momentum for Travere Therapeutics’ Stock Price

Life Science

Looking for a “Forever” Stock? These 2 Healthcare Picks Are Worth Considering

Life Science